ゲノム編集市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、技術別、送達方法別、用途別、地域別、競合別分析

世界のゲノム編集市場は2022年に50億8,000万米ドルと評価され、2028年までのCAGRは6.45%で、予測期間中に目覚ましい成長を遂げると予測されています。

ゲノム編集市場は、バイオ技術革新の最前線で急速に拡大している分野であり、遺伝子研究、治療開発、個別化医療の展望に革命をもたらしています。ゲノム編集には生物のDNAを正確に改変することが含まれ、分子レベルで遺伝物質を操作・修正する比類のない機会が提供されます。

ゲノム編集市場の主な促進要因の1つは、治療への応用がもたらす変革の可能性です。画期的なゲノム編集技術であるCRISPR-Cas9は、精密な遺伝子編集のための強力なツールとして登場しました。CRISPR-Cas9は、研究者や臨床医が特定のDNA配列を改変し、さまざまな疾患に関連する遺伝子変異を修正または除去することを可能にします。これによって、遺伝性疾患、がん、その他遺伝的基盤を持つ無数の疾患に対する標的療法開発の道が開かれました。同市場では、学術界と産業界の研究活動や共同研究が活発化しており、ゲノム編集技術の進歩に拍車をかけています。より効率的で正確なツールの需要は、CRISPR-Cas12、CRISPR-Cas13、塩基編集技術など、CRISPR-Cas9以外の新規編集システムの開発につながった。これらの技術革新は、オフターゲット効果や送達の課題に関連する限界に対処するものであり、治療開発におけるゲノム編集の応用可能性を拡大するものです。ゲノム編集は治療的介入だけにとどまらず、農業バイオテクノロジーにおいても極めて重要な役割を果たしています。収量の向上、害虫に対する抵抗性、栄養プロファイルの改善などを備えた遺伝子組み換え作物の開発は、主要な重点分野です。CRISPRベースの技術を用いて植物ゲノムを精密に編集する能力は、持続可能な農業と食糧安全保障にとって広範な意味を持ち、農業分野におけるゲノム編集技術の採用を後押ししています。

治療や農業への応用に加えて、ゲノム編集市場は研究目的での需要の急増を目の当たりにしています。この技術により、科学者は遺伝子組み換え生物の作成、遺伝子機能の研究、複雑な遺伝経路の解明が可能になります。その結果、学術・研究機関がゲノム編集ツールを研究に取り入れるケースが増えており、市場を前進させています。その大きな可能性にもかかわらず、ゲノム編集市場は倫理的・規制的課題に直面しています。ヒトの生殖系列を編集し、次世代に受け継がれる改変を可能にする能力は、倫理的な懸念を引き起こし、責任ある使用についての議論を促しています。規制の枠組みは、こうした倫理的配慮に対処し、ゲノム編集技術の安全かつ倫理的な応用を確保するために発展しつつあります。

同市場は競争も激しく、主要企業は技術進歩の最前線にとどまるために研究開発に多額の投資を行っています。各社は、製品ポートフォリオを強化し、世界のプレゼンスを拡大するため、戦略的提携やパートナーシップを模索しています。さらに、市場に参入するバイオテクノロジー新興企業の増加は、革新的なアイデアやアプローチが継続的に流入する活気あるエコシステムを示しています。今後、ゲノム編集市場は、継続的な技術の進歩、治療開発および農業における応用の拡大、精密医療の重視の高まりに牽引され、持続的な成長を遂げる構えです。倫理的・規制的状況が進化するにつれて、市場はゲノム編集技術の責任ある倫理的使用へのパラダイムシフトし、新たな可能性を解き放ち、人間の健康、農業、科学研究の進歩に貢献することが期待されます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別（Crispr、Zfn、Talen）
  • 送達方法別（生体外、生体内）
  • 用途別（遺伝子工学、臨床応用）
  • 地域別
  • 企業別（2022年）
• 市場マップ
  • 技術別
  • 送達方法別
  • 用途別
  • 地域別

第5章 アジア太平洋のゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 提供方法別
  • 用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 送達方法別
  • 用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別
  • 送達方法別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 送達方法別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのゲノム編集市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 技術別
  • 送達方法別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• デリバリー方法の発売
• 合併と買収

第12章 世界のゲノム編集市場SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Cibus Inc
  • Business Overview
  • Company Snapshot
  • Delivery Method & Services
  • Current Capacity Analysis
  • Financials（In case of listed）
  • Recent Developments
  • SWOT Analysis
• リコンビネティクス社
• メルク社
• サンガモ・セラピューティクス社
• エディタスメディシン
• プレシジョン・バイオサイエンシズ社
• CRISPRセラピューティクス社
• インテリア・セラピューティクス社
• カリブー・バイオサイエンシズ社
• タカラバイオ

第15章 戦略的提言

第16章 調査会社・免責事項

Global Genome Editing Market has valued at USD 5.08 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.45% through 2028. The Genome Editing Market is a rapidly expanding sector at the forefront of biotechnological innovation, revolutionizing the landscape of genetic research, therapeutic development, and personalized medicine. Genome editing involves precise modification of an organism's DNA, offering unparalleled opportunities to manipulate and correct genetic material at the molecular level.

One of the primary drivers of the Genome Editing Market is the transformative potential it holds for therapeutic applications. CRISPR-Cas9, a groundbreaking genome editing technology, has emerged as a powerful tool for precise gene editing. It enables researchers and clinicians to modify specific DNA sequences, correcting or eliminating genetic mutations associated with various diseases. This has opened avenues for the development of targeted therapies for genetic disorders, cancer, and a myriad of other diseases with a genetic basis. The market is witnessing increased research activities and collaborations across academia and industry, fueling advancements in genome editing technologies. The demand for more efficient and accurate tools has led to the development of novel editing systems beyond CRISPR-Cas9, including CRISPR-Cas12, CRISPR-Cas13, and base editing technologies. These innovations address limitations associated with off-target effects and delivery challenges, expanding the potential applications of genome editing in therapeutic development. Genome editing is not confined to therapeutic interventions alone; it plays a pivotal role in agricultural biotechnology. The development of genetically modified crops with enhanced yield, resistance to pests, and improved nutritional profiles is a key focus area. The ability to precisely edit plant genomes using CRISPR-based technologies has far-reaching implications for sustainable agriculture and food security, driving the adoption of genome editing techniques in the agricultural sector.

In addition to therapeutic and agricultural applications, the Genome Editing Market is witnessing a surge in demand for research purposes. The technology enables scientists to create genetically modified organisms, study gene functions, and unravel the complexities of genetic pathways. As a result, academic and research institutions are increasingly incorporating genome editing tools into their studies, propelling the market forward. Despite its immense potential, the Genome Editing Market faces ethical and regulatory challenges. The ability to edit the human germline, allowing modifications that can be passed down to future generations, raises ethical concerns and prompts discussions about responsible use. Regulatory frameworks are evolving to address these ethical considerations and ensure the safe and ethical application of genome editing technologies.

The market is also characterized by intense competition, with key players investing significantly in research and development to stay at the forefront of technological advancements. Companies are exploring strategic collaborations and partnerships to enhance their product portfolios and expand their global presence. Moreover, the increasing number of biotechnology startups entering the market indicates a vibrant ecosystem with a continuous influx of innovative ideas and approaches. Looking ahead, the Genome Editing Market is poised for sustained growth, driven by ongoing technological advancements, increasing applications in therapeutic development and agriculture, and a growing emphasis on precision medicine. As the ethical and regulatory landscape evolves, the market is expected to witness a paradigm shift toward responsible and ethical use of genome editing technologies, unlocking new possibilities and contributing to advancements in human health, agriculture, and scientific research.

Key Market Drivers

Therapeutic Advancements

Therapeutic advancements stand as a primary driving force propelling the Genome Editing Market into a new era of medical innovation. Central to this progression is the revolutionary CRISPR-Cas9 technology, which has become a game-changer in the field of gene editing. This tool allows researchers and clinicians to precisely modify DNA sequences, correcting or eliminating genetic mutations associated with various diseases. The implications for therapeutic applications are profound, opening avenues for the development of targeted treatments for genetic disorders, cancer, and a host of other ailments rooted in genetic anomalies. The precision and versatility of CRISPR-Cas9 enable scientists to address previously challenging therapeutic scenarios. The technology's ability to navigate and edit the human genome with unprecedented accuracy offers a transformative approach to treating diseases at their genetic source. This precision is particularly crucial in the realm of genetic disorders, where correcting specific mutations can potentially alleviate or eliminate the underlying cause of the condition.

The Genome Editing Market's trajectory is intricately tied to the progress in therapeutic applications, as researchers continually explore new ways to leverage genome editing technologies for medical breakthroughs. This includes ongoing developments in ex vivo gene editing, where cells are edited outside the body before being reintroduced, and in vivo gene editing, which allows direct editing within the patient's body.

The market is witnessing a surge in research focused on expanding the range of treatable conditions. From rare genetic disorders to more common ailments with a genetic basis, therapeutic advancements in genome editing are unlocking possibilities that were once deemed elusive. The prospect of personalized medicine, tailored to an individual's genetic makeup, is becoming increasingly feasible, with genome editing playing a central role in this paradigm shift. As therapeutic applications continue to drive the Genome Editing Market, collaborations between research institutions, biotechnology companies, and healthcare providers are intensifying. The goal is not just to develop innovative treatments but to establish a foundation for a new era of precision medicine, where genome editing becomes a cornerstone in the arsenal of therapeutic interventions, offering hope for patients with previously untreatable genetic conditions.

Agricultural Biotechnology

Agricultural biotechnology is a significant driving force behind the rapid expansion of the Genome Editing Market, playing a pivotal role in reshaping global agriculture. Genome editing technologies, particularly CRISPR-based systems, have emerged as powerful tools for precise genetic modifications in crops, offering unparalleled opportunities to enhance agricultural productivity, sustainability, and food security. The ability to precisely edit plant genomes addresses longstanding challenges in traditional crop breeding. Genome editing enables scientists to introduce desirable traits, such as increased yield, resistance to pests and diseases, and improved nutritional content, with unparalleled accuracy. Unlike conventional breeding methods, genome editing allows for targeted modifications without introducing foreign genes, resulting in crops that are more readily accepted by regulatory bodies and consumers.

CRISPR-based genome editing technologies are increasingly adopted by the agricultural sector to create crops with improved characteristics. These advancements are particularly crucial as global populations continue to rise, placing greater demands on agricultural systems. The potential to develop crops that are resilient to changing climate conditions, require fewer chemical inputs, and possess enhanced nutritional profiles has positioned genome editing as a cornerstone in addressing the evolving challenges faced by modern agriculture. The Genome Editing Market's connection to agricultural biotechnology extends beyond crop improvement. Livestock and aquaculture industries also stand to benefit from genome editing, with applications ranging from disease resistance in animals to enhancing the nutritional content of food products.

As the demand for sustainable and efficient agricultural practices intensifies, genome editing technologies are becoming indispensable tools for researchers, agronomists, and biotechnologists. The Genome Editing Market's growth in the agricultural sector is not only a testament to the transformative potential of these technologies but also reflects a global commitment to harnessing biotechnology for the benefit of food production, environmental sustainability, and meeting the nutritional needs of a burgeoning global population. The convergence of agricultural biotechnology and genome editing marks a paradigm shift in how we approach crop improvement, heralding a new era in precision agriculture with far-reaching implications for the future of food production.

Key Market Challenges

Off-Target Effects and Precision Issues

Off-target effects and precision issues pose a formidable challenge for the Genome Editing Market. Achieving absolute precision in modifying DNA without inadvertently affecting non-targeted areas remains a significant hurdle. Unintended alterations in the genome, known as off-target effects, can lead to unpredictable consequences, including the introduction of mutations or disruptions in critical genetic sequences. Overcoming these challenges is imperative for ensuring the safety and efficacy of genome editing applications, particularly in therapeutic contexts. Ongoing research and technological innovations are focused on minimizing off-target effects, enhancing precision, and improving the overall accuracy of genome editing tools.

Delivery Challenges

Delivery challenges present a significant obstacle for the Genome Editing Market. Efficiently delivering genome editing tools, such as CRISPR-Cas9, to specific cells or tissues is a complex task, especially in in vivo applications. Ensuring that these tools reach their intended targets with precision is crucial for the success of therapeutic and clinical applications. Overcoming barriers related to the targeted delivery of genome editing machinery, including issues of specificity, efficiency, and minimizing potential off-target effects, remains a forefront challenge. Ongoing research focuses on developing advanced delivery systems to enhance the effectiveness and applicability of genome editing technologies in diverse contexts.

Ethical Considerations

Ethical considerations present a formidable challenge for the Genome Editing Market, particularly concerning the ability to edit the human germline. The potential for heritable genetic modifications raises profound ethical concerns, including questions about safety, unintended consequences, and the societal impact of altering the human genome. Balancing the promise of therapeutic breakthroughs with the need for responsible and ethical use poses a complex dilemma for researchers, policymakers, and society at large. Establishing universally accepted ethical guidelines and navigating public perceptions are critical for fostering trust and ensuring the ethical advancement of genome editing technologies in both clinical and research settings.

Regulatory Frameworks

Regulatory frameworks pose a significant challenge for the Genome Editing Market. Harmonizing global regulations to govern the ethical and safe use of genome editing technologies is complex. Varying regulatory approaches in different regions create uncertainties, impacting research, development, and commercialization. Striking a balance between fostering innovation and ensuring safety requires clear, consistent, and globally accepted regulatory standards. Establishing robust frameworks that address ethical considerations, potential risks, and responsible use is imperative for instilling confidence among stakeholders and facilitating the market's growth. Ongoing efforts to navigate these regulatory challenges are crucial for advancing genome editing technologies responsibly and ethically.

Key Market Trends

Advanced CRISPR-Based Technologies

The trend of advanced CRISPR-based technologies is reshaping the Genome Editing Market. Beyond the pioneering Cas9 system, the development of CRISPR-based tools like Cas12 and Cas13 signifies a pivotal advancement. These technologies address limitations associated with off-target effects and broaden the scope of applications in therapeutic and research contexts. The pursuit of enhanced precision reduced unintended genomic alterations, and expanded capabilities for manipulating genetic material marks a crucial trend. Researchers and biotechnologists are leveraging these innovations to unlock new possibilities in gene editing, paving the way for more accurate and versatile genome editing tools with far-reaching implications across diverse sectors.

In Vivo Genome Editing

In vivo genome editing has emerged as a transformative trend in the Genome Editing Market, revolutionizing therapeutic possibilities. This trend involves directly editing the patient's genetic material within the body, a significant departure from traditional ex vivo approaches. Advancements in delivery systems, including nanoparticles and viral vectors, facilitate more efficient and targeted in vivo genome editing. This trend holds immense promise for treating genetic disorders, as it allows for precise modifications within the physiological context. The growing focus on in vivo applications reflects a paradigm shift in therapeutic strategies, offering unprecedented potential for developing novel and personalized treatments directly within the patient's biological environment.

Therapeutic Applications in Genetic Disorders

The trend of therapeutic applications in genetic disorders is a driving force in the Genome Editing Market. Genome editing technologies, particularly CRISPR-based systems, are increasingly focused on correcting or eliminating mutations associated with hereditary diseases. This trend represents a significant stride towards personalized medicine, offering targeted and precise interventions for individuals with genetic disorders. Researchers and biotech companies are actively exploring the therapeutic potential of genome editing, bringing about a paradigm shift in the treatment of genetic conditions. The ongoing trend underscores the market's commitment to advancing innovative solutions for previously challenging and incurable genetic disorders.

Expansion in Agriculture Biotechnology

Expansion in agriculture biotechnology stands out as a pivotal trend in the Genome Editing Market. Genome editing is increasingly applied to enhance crop traits, such as yield, resistance to pests, and nutritional content. This trend reflects a broader impact on sustainable agriculture and food security. CRISPR-based technologies enable precise modifications in plant genomes, offering a powerful tool for creating genetically modified crops with desirable characteristics. Efforts to address global food challenges and promote environmentally sustainable farming practices are propelling the expansion of genome editing applications in agriculture biotechnology, marking a crucial trend that aligns with evolving agricultural needs and technological capabilities.

Segmental Insights

Technology Insights

Based on the Technology, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) stands as the dominant force in the Genome Editing Market due to its unparalleled precision, versatility, and ease of use. The simplicity of CRISPR-based technologies, particularly CRISPR-Cas9, allows researchers and biotechnologists to target specific genes with remarkable accuracy, enabling efficient modifications. Its widespread adoption in diverse applications, from therapeutic interventions to agricultural biotechnology, showcases its transformative potential. CRISPR's accessibility, cost-effectiveness, and continuous improvements, including advanced variations like Cas12 and Cas13, position it at the forefront of genome editing, driving innovation and shaping the landscape of genetic research, therapeutics, and biotechnology.

Delivery Method Insights

Ex-vivo genome editing dominates the Genome Editing Market due to its established success in therapeutic applications. In ex-vivo editing, cells are modified outside the body before being reintroduced, allowing for precise genetic alterations. This approach is particularly effective in treating genetic disorders, as it permits thorough editing and quality control before administering modified cells to patients. Ex-vivo strategies, often employing CRISPR-based technologies, have demonstrated notable success in clinical trials for conditions like sickle cell anemia and beta-thalassemia. The method's proven efficacy, safety, and ongoing advancements solidify its dominance in therapeutic genome editing, paving the way for transformative medical interventions.

Regional Insights

North America's dominance in the Genome Editing Market can be attributed to a confluence of factors, including robust research infrastructure, substantial investment, and a thriving biotechnology landscape. The region boasts leading biotech companies, research institutions, and pharmaceutical giants actively engaged in advancing genome editing technologies. Extensive funding from government bodies and private investors fuels research initiatives, fostering innovation. Additionally, supportive regulatory frameworks and a culture of technological adoption contribute to the market's prominence. The concentration of key players, strategic collaborations, and a high level of research activity collectively position North America as a hub for genome editing advancements, driving market leadership.

Key Market Players

Cibus Inc

Recombinetics, Inc

Merck & Co., Inc

Sangamo Therapeutics Inc

Editas Medicine Inc

Precision BioSciences Inc

CRISPR Therapeutics Inc

Intellia Therapeutics, Inc

Caribou Biosciences, Inc

Takara Bio Inc

Report Scope:

In this report, the Global Genome Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genome Editing Market, By Technology:

• Crispr
• Zfn
• Talen

Genome Editing Market, By Delivery Method:

• Ex-vivo
• In-vivo

Genome Editing Market, By Application:

• Genetic Engineering
• Clinical Applications

Genome Editing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies presents in the Genome Editing Market.

Available Customizations:

• Global Genome Editing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Genome Editing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Technology (Crispr, Zfn, Talen)
  • 4.2.2. By Delivery Method (Ex-vivo, In-vivo)
  • 4.2.3. By Application (Genetic Engineering, Clinical Applications)
  • 4.2.4. By Region
  • 4.2.5. By Company (2022)
• 4.3. Market Map
  • 4.3.1. By Technology
  • 4.3.2. By Delivery Method
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Genome Editing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology
  • 5.2.2. By Delivery Method
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Genome Editing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Technology
      • 5.3.1.2.2. By Delivery Method
      • 5.3.1.2.3. By Application
  • 5.3.2. India Genome Editing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Technology
      • 5.3.2.2.2. By Delivery Method
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Genome Editing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Technology
      • 5.3.3.2.2. By Delivery Method
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Genome Editing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Technology
      • 5.3.4.2.2. By Delivery Method
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Genome Editing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Technology
      • 5.3.5.2.2. By Delivery Method
      • 5.3.5.2.3. By Application

6. Europe Genome Editing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Delivery Method
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Genome Editing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Delivery Method
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Genome Editing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Delivery Method
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Genome Editing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Delivery Method
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Genome Editing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Delivery Method
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Genome Editing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Delivery Method
      • 6.3.5.2.3. By Application

7. North America Genome Editing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Delivery Method
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Genome Editing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Delivery Method
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Genome Editing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Delivery Method
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Genome Editing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Delivery Method
      • 7.3.3.2.3. By Application

8. South America Genome Editing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Delivery Method
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Genome Editing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Delivery Method
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Genome Editing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Delivery Method
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Genome Editing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Delivery Method
      • 8.3.3.2.3. By Application

9. Middle East and Africa Genome Editing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Delivery Method
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Genome Editing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Delivery Method
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Genome Editing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Delivery Method
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Genome Editing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Delivery Method
      • 9.3.3.2.3. By Application
  • 9.3.4. Egypt Genome Editing Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Technology
      • 9.3.4.2.2. By Delivery Method
      • 9.3.4.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Delivery Method Launches
• 11.3. Mergers & Acquisitions

12. Global Genome Editing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Delivery Method

14. Competitive Landscape

• 14.1. Cibus Inc
  • 14.1.1.1. Business Overview
  • 14.1.1.2. Company Snapshot
  • 14.1.1.3. Delivery Method & Services
  • 14.1.1.4. Current Capacity Analysis
  • 14.1.1.5. Financials (In case of listed)
  • 14.1.1.6. Recent Developments
  • 14.1.1.7. SWOT Analysis
• 14.2. Recombinetics, Inc
• 14.3. Merck & Co., Inc
• 14.4. Sangamo Therapeutics Inc
• 14.5. Editas Medicine Inc
• 14.6. Precision BioSciences Inc
• 14.7. CRISPR Therapeutics Inc
• 14.8. Intellia Therapeutics, Inc
• 14.9. Caribou Biosciences, Inc
• 14.10. Takara Bio Inc

15. Strategic Recommendations

16. About Us & Disclaimer